NewLimit, a longevity research company co-founded by Coinbase CEO, has secured $45 million in additional funding. The investment round saw participation from Lilly Ventures, Duke University, S32, and Abstract, along with existing investors like Kleiner Perkins and Boost VC. This funding follows a technological breakthrough in NewLimit's project aimed at restoring youthful liver function, with clinical studies planned for the near future.
NewLimit Raises $45 Million to Advance Longevity Research
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.